Gene and cell therapies are treatments that alter genetic material or use living cells to prevent, repair, replace, or fight disease. Together, they are moving medicine beyond repeatedly managing symptoms toward addressing some underlying biological causes. The United States Food and Drug Administration (FDA) has approved more than 30 cell and gene therapy products, including treatments for inherited blood disorders, childhood neurodegenerative disease, cancer, blindness, and cartilage damage. Their future will depend on whether researchers and health systems can improve durability, manufacturing, safety, affordability, and access while demonstrating value for patients and society.

Treatment Innovation and Gene and Cell Therapies

The National Cancer Institute defines gene therapy as a treatment that modifies a person’s genes to treat or cure disease. Cell therapy, by contrast, uses living cells introduced into a patient to repair tissue, replace damaged cells, regulate immunity, or attack disease. Gene and cell therapies overlap when cells are genetically modified before they are returned to the patient, as in chimeric antigen receptor T-cell, or CAR-T, therapy.

The pairing includes several related treatment categories: in vivo gene therapy, which delivers genetic material directly inside the body; ex vivo gene therapy, which modifies cells outside the body before infusion; genome editing, which changes DNA at a selected location; somatic cell therapy, which affects the treated individual rather than future descendants; and regenerative cell therapy, which aims to restore damaged tissue. These hyponyms differ in mechanism, but they share a goal: producing a therapeutic biological effect that may last substantially longer than the effect of a conventional drug.

This distinction is important because traditional medicines generally work through repeated dosing, whereas many advanced therapies are designed as one-time or limited-course interventions. A therapy may therefore have a high initial price but reduce years of hospitalizations, transfusions, immunosuppression, or disease progression. The Institute for Clinical and Economic Review has emphasized that assessing these products requires long-term evidence, not only the cost of the first treatment.

Gene Replacement and Gene Addition

Gene replacement and gene addition supply functional genetic instructions when a patient’s gene is missing, defective, or insufficiently active. Viral vectors, especially adeno-associated viruses and lentiviruses, are commonly engineered to carry therapeutic genetic material while limiting their ability to cause disease. Examples include Luxturna for a form of inherited retinal disease, Zolgensma for spinal muscular atrophy, and Hemgenix for hemophilia B.

The clinical value of this approach is clearest in rare monogenic disorders, where one pathogenic gene can have a direct relationship with disease. The FDA describes Zolgensma as a single-dose treatment for children with spinal muscular atrophy caused by mutations in the SMN1 gene. In clinical studies, treated infants showed substantially improved survival and motor milestones compared with the expected natural history of the disease.

Genome Editing

Genome editing uses molecular tools such as CRISPR-associated proteins to cut, replace, silence, or otherwise modify DNA. In December 2023, the FDA approved Casgevy, the first U.S.-approved therapy using CRISPR-based genome editing, for certain patients aged 12 and older with sickle cell disease. The treatment edits a patient’s blood-forming stem cells outside the body so they produce more fetal hemoglobin, reducing the tendency of red blood cells to sickle.

Casgevy illustrates both the promise and complexity of editing. The therapy is not a simple injection: patients typically undergo stem-cell collection, laboratory editing, conditioning chemotherapy, and reinfusion, followed by extended monitoring. Clinical trial results reported by the FDA showed that 29 of 31 evaluable patients maintained freedom from severe vaso-occlusive crises for at least 12 consecutive months during the primary assessment period. Long-term surveillance remains essential because unintended edits, delayed toxicities, and the durability of benefit may take years to evaluate.

Disease Modification and Cell-Based Treatment

Cell-based treatment uses living cells as the therapeutic agent. The cells may replace tissue, secrete beneficial proteins, regulate inflammation, or recognize and destroy abnormal cells. The most established examples are hematopoietic stem-cell transplantation and engineered immune-cell therapies. Researchers are also developing pancreatic islet cells for diabetes, retinal cells for vision loss, cartilage cells for joint injury, and neural cells for Parkinson’s disease.

CAR-T Cancer Therapy

CAR-T therapy is an ex vivo cell therapy in which a patient’s T cells are collected, genetically modified to recognize a cancer-associated target, expanded in a manufacturing facility, and returned to the patient. The FDA first approved a CAR-T product in 2017. By 2024, six CAR-T products had received FDA approval for several blood cancers, including certain leukemias, lymphomas, and multiple myeloma.

The therapy has produced durable remissions in some patients whose cancer returned after multiple previous treatments. Its risks include cytokine release syndrome, in which activated immune cells trigger intense inflammation, and immune effector cell-associated neurotoxicity syndrome. The FDA has also required safety monitoring for rare secondary T-cell malignancies associated with some genetically modified cell therapies. These risks demonstrate why innovation must be matched by specialized treatment centers, rapid diagnosis, and long-term follow-up.

Regenerative and Replacement Cell Therapy

Regenerative cell therapy seeks to restore structure or function by replacing cells lost through disease or injury. In 2024, the FDA approved Lenmeldy, an autologous gene therapy for certain children with metachromatic leukodystrophy, and Amtagvi, the first FDA-approved tumor-derived T-cell immunotherapy for a solid tumor. The approvals show that cell and gene therapies are expanding beyond rare enzyme deficiencies and blood cancers.

Other approaches remain investigational. Stem-cell-derived pancreatic islet cells may eventually reduce or eliminate the need for injected insulin in selected people with type 1 diabetes, while induced pluripotent stem cells may provide patient-specific sources for heart, nerve, or retinal repair. However, researchers must still solve problems involving immune rejection, incomplete cell maturation, uncontrolled growth, vascular integration, and the reliable production of billions of correctly differentiated cells.

Clinical Evidence and Gene and Cell Therapies

Clinical evidence for these therapies is often built differently from evidence for conventional drugs. Rare diseases may have too few patients for large randomized trials, and rapidly progressive disorders may make placebo-controlled studies ethically difficult. Regulators can therefore use surrogate endpoints, historical controls, or accelerated approval pathways, but these approaches increase the importance of post-approval studies.

The FDA’s Cellular and Gene Therapy Products office evaluates product quality, clinical benefit, manufacturing consistency, and safety. The agency has also used long-term follow-up requirements because genetic changes or persistent cells can remain in the body for many years. A key future metric will not simply be the number of approvals; it will be the proportion of patients who maintain meaningful benefit over five, ten, or more years.

Evidence From Sickle Cell Disease

Sickle cell disease is a useful case study because it combines a well-understood genetic cause, severe lifelong complications, and measurable clinical outcomes. The Centers for Disease Control and Prevention estimates that sickle cell disease affects approximately 100,000 people in the United States. Before advanced therapies, many patients required repeated transfusions, pain treatment, and hospital care, while some developed organ damage at a young age.

Casgevy and Lyfgenia, another FDA-approved gene therapy for sickle cell disease, offer the possibility of reducing severe crises. Yet access requires specialized hospitals, cell-processing capacity, chemotherapy preparation, and extensive insurance coordination. The case therefore demonstrates that medical efficacy alone does not guarantee practical availability.

Evidence From Cancer

Cancer illustrates the potential of living medicines to adapt to changing disease biology. CAR-T cells can expand inside the patient after infusion and may continue patrolling for malignant cells. In some B-cell malignancies, complete response rates in pivotal trials have been substantial, although relapse can occur when cancer cells lose the targeted antigen or when the infused cells become exhausted.

The next generation of cancer cell therapies is likely to include armored CAR-T cells, T-cell receptor therapies, natural killer cell products, and allogeneic “off-the-shelf” cells from donors. These approaches could reduce manufacturing time and cost, but they must address graft-versus-host disease, immune rejection, tumor targeting, and genetic stability.

Access, Safety, and Gene and Cell Therapies

Affordability is one of the most visible challenges. Several approved products have list prices in the millions of dollars: Hemgenix launched at approximately $3.5 million, Zolgensma at approximately $2.125 million, and Lenmeldy at approximately $4.25 million. These prices do not necessarily represent the total societal cost or the final amount paid by an insurer, but they show why payment models must account for long-term outcomes.

Potential solutions include outcomes-based contracts, installment payments, reinsurance arrangements, public coverage guarantees, and expanded newborn screening. Such models are difficult because a patient may change insurers, move between health systems, or require monitoring for decades. Health economists and policymakers must also consider patients who are eligible but cannot reach an authorized treatment center.

Manufacturing and Supply Chains

Manufacturing is part of the treatment rather than a separate background process. Autologous therapies require an individual patient’s cells to be collected, labeled, transported, modified, tested, returned, and administered without mix-ups or damaging delays. Viral-vector therapies require highly controlled production and testing for potency, purity, identity, and contamination.

The industry is responding with automated closed systems, standardized manufacturing platforms, decentralized processing, cryopreservation, and donor-derived products. These improvements could shorten turnaround times and reduce manufacturing failures. They may also make advanced therapies more practical for regional hospitals rather than only a small number of academic centers.

Ethics and Long-Term Responsibility

Most approved therapies modify somatic cells, meaning the changes are not intended to pass to future generations. Germline editing, which could be inherited by descendants, remains ethically and legally restricted in many jurisdictions. The distinction is fundamental: somatic therapy treats an individual patient, while germline intervention could affect people who cannot consent and future populations.

Responsible development also requires informed consent that explains uncertainty, not merely potential benefit. Patients should understand the possibility of infertility from conditioning chemotherapy, hospitalization, delayed adverse effects, secondary malignancy, treatment failure, and the need for lifelong follow-up. Equity must be considered in clinical-trial recruitment, genetic testing, newborn screening, and access for communities historically underrepresented in biomedical research.

Future Outlook for Gene and Cell Therapies

The next decade is likely to bring more precise editing, improved delivery systems, safer viral and nonviral vectors, and increasingly programmable immune cells. Base editing and prime editing may correct certain DNA changes without creating the double-strand breaks used by earlier CRISPR methods. Messenger RNA, lipid nanoparticles, and targeted delivery could allow temporary genetic instructions to reach selected organs without permanently altering every treated cell.

Artificial intelligence may help identify disease-causing mutations, design guide RNAs, predict protein interactions, select patients, and detect manufacturing abnormalities. However, computational predictions must be confirmed through laboratory studies and carefully designed clinical trials. The most successful future products will probably combine molecular precision with simple delivery, scalable manufacturing, and clear evidence of patient-centered benefit.

A useful way to visualize the field is a four-part comparison: gene addition supplies missing instructions; genome editing changes existing instructions; cell therapy supplies living biological functions; and engineered cell therapy combines genetic programming with a living treatment platform. This conceptual chart shows why no single technology will replace all others. Different diseases require different balances of permanence, precision, reversibility, immune compatibility, and manufacturing complexity.

Conclusion: Treatment’s Transition Through Gene and Cell Therapies

Gene and cell therapies are redefining treatment innovation by turning genes and living cells into therapeutic tools. Gene replacement can restore missing biological functions, genome editing can correct or redirect cellular behavior, CAR-T therapy can mobilize the immune system against cancer, and regenerative approaches may replace damaged tissue. FDA approvals for products such as Casgevy, Zolgensma, Luxturna, Hemgenix, CAR-T therapies, Lenmeldy, and Amtagvi show that this future is already entering clinical practice.

Their broader significance will be measured by more than scientific novelty. Durable safety, equitable access, sustainable payment, reliable manufacturing, transparent evidence, and long-term patient support will determine whether these therapies become routine medicine or remain limited to highly specialized settings. Patients and families should consult qualified clinicians and trusted regulatory or disease-specific organizations, while researchers and policymakers should prioritize long-term registries, diverse trials, and infrastructure that makes transformative treatment available to the people who need it.

Sources: U.S. Food and Drug Administration, Cellular & Gene Therapy Products, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products; U.S. Food and Drug Administration, FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease; U.S. Food and Drug Administration, FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy; National Cancer Institute, Gene Therapy, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/gene-therapy; National Cancer Institute, CAR T-Cell Therapy, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells; Centers for Disease Control and Prevention, Sickle Cell Disease, https://www.cdc.gov/sickle-cell/about/index.html; Institute for Clinical and Economic Review, 2024-2025 Value Assessment Framework, https://icer.org/healthcare-cost-and-value/2024-2025-value-assessment-framework/; U.S. Food and Drug Administration, FDA Approves Novel Gene Therapy to Treat Patients with Duchenne Muscular Dystrophy, https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-duchenne-muscular-dystrophy